T cell recognition of melanoma antigens in association with HLA-A1 on allogeneic melanoma cells

Previous studies have shown that recognition of melanoma by cytotoxic T lymphocytes may be restricted by HLA-A1, A2 and other HLA antigens. The present study examined the cytotoxic specificity and major histocompatibility complex restriction of cloned cytotoxic T lymphocytes (CTL) isolated from a patient with the HLA phenotype A3,31 who had been immunized with a vaccine prepared from HLA-A1,3 melanoma cells. Cytotoxic assays against HLA-typed allogeneic melanoma cells indicated that cloned CTL from the patient were able to kill allogeneic melanoma cells expressing HLA-A1 but not other HLA-A1-positive cells. Studies on a representative clone indicated that proliferation and cytokine (tumour necrosis factor ) production in response to melanoma cells was also associated with HLA-A1 on melanoma cells. Response to the melanoma cells was associated with interleukin-4 (IL-4) rather than IL-2 production. The antigen recognized in the context of HLA-A1 on allogeneic melanoma cells was detected in cytotoxic assays on cells from 9 of 12 HLA-A1⁺ melanoma cell lines and did not appear to be the product of the MAGE-1 or-3 genes. These findings suggest that T cells can recognize melanoma antigens in the context of alloantigens and that allogeneic vaccines containing immunodominant alloantigens may generate CTL that are ineffective against autologous melanoma. The study does not, however, exclude the possibility that CTL with specificity to the latter may be activated by allogeneic vaccines, and further studies are needed to answer this question.     

低剂量CO2激光对茄子,青椒叶绿体超微结构影响的初步观察

本试验用功率密度为825mw/cm~2的CO_2激光照射茄子干种子(含水量8.33％)13s、青椒干种子(含水量5.4％)3s,分别以Os为对照(ck)。照射后播于生长箱内,出苗10天分苗于玻璃温室内,于四叶期取样观察成熟叶片叶绿体的超微结构。发现激光照射处理的茄子、青椒的叶绿体的基质片层、基粒片层有明显的吸胀现象。     

Requirements for human embryonic stem cells

‘Requirements for Human Embryonic Stem Cells’ is the first set of guidelines on human embryonic stem cells in China, jointly drafted and agreed upon by experts from the Chinese Society for Stem Cell Research. This standard specifies the technical requirements, test methods, test regulations, instructions for use, labelling requirements, packaging requirements, storage requirements and transportation requirements for human embryonic stem cells, which is applicable to the quality control for human embryonic stem cells. It was originally released by the China Society for Cell Biology on 26 February 2019 and was further revised on 30 April 2020. We hope that publication of these guidelines will promote institutional establishment, acceptance and execution of proper protocols, and accelerate the international standardization of human embryonic stem cells for applications.     

基于生态系统评价的山水林田湖草生态保护与修复体系构建研究——以乌梁素海流域为例

山水林田湖草系统保护与修复工程实施的重要目标是维护和提升区域生态系统服务。从乌梁素海流域山水林田湖草的生态现状与功能出发,对乌梁素海流域水土流失、土地沙化等生态敏感性及土壤保持、水源涵养、生物多样性等生态功能重要性进行系统评价,形成基于生态敏感性和生态功能重要性相结合的空间格局评价结果。以维护和提升人类福祉所需的重要生态系统服务为目标,以乌梁素海流域生态敏感性和生态功能重要性相结合的空间格局评价结果为基础,制定了“一中心、二重点、六要素、七工程”的乌梁素海山水林田湖草生态保护与修复体系,并基于此将乌梁素海流域生态保护修复分为6个主要治理区域,形成“四区、一带、一网”的生态安全格局,通过具体工程实施,流域生态环境质量和生态服务能力将取得明显提升,防风固沙能力有效增强,生物多样性持续改善,水环境质量稳定达标,生态系统的稳定性明显加强。通过乌梁素海流域的分析案例为流域山水林田湖草生态保护与修复关键区域的识别提供了定量分析方法,为流域尺度构建生态安全格局、实现山水林田湖草系统保护和修复提供思路和途径。     

非生长季降水对青藏高原高寒草甸优势种生物量稳定性的影响

受全球气候变化的影响,青藏高原在过去的几十年间整体上呈现暖湿化的趋势,相比于年际之间温度和降水的变化外,生长季和非生长季气候变化模式的差异可能会对生态系统产生更重要的影响,但相关的研究尚不充分。以青藏高原东部的高寒草甸为研究对象,基于2001年至2017年17年的野外观测数据,包括优势植物紫花针茅的高度、多度以及生物量、次优势物种洽草的生物量,结合生长季和非生长季平均温度和降水量的变化,通过线性回归以及结构方程模型,探究生长季/非生长季不对称气候变化对于青藏高原高寒草甸优势物种生物量稳定性的影响。研究结果表明：1)青藏高原东部年均温和年降水在过去的17年间显著增加,呈现暖湿化的趋势,但是非生长的降水却变化不明显;2)紫花针茅的高度、多度以及生物量在过去17年没有显著的趋势,但是洽草的生物量稳定性显著减少;3)非生长降水结合紫花针茅的高度、多度以及洽草的生物量稳定性促进了紫花针茅的生物量稳定性。研究结果可以为青藏高原高寒草甸在未来气候变化的背景下合理保护与利用提供科学依据。     

海洋野生鱼酶解提取鱼油的工艺分析

海洋野生鱼与养殖鱼比较, 其鱼油中含更多的二十碳五烯酸（EPA）、二十二碳六烯酸（DHA）、脂溶性维生素等活性成分。为提高海洋野生鱼的利用价值, 以野生小带鱼为原料进行酶法提油工艺研究。分析了不同的温度, 时间, pH值等影响因素下的提取、萃取以及离心效果, 以响应面法确定了最佳的酶解工艺条件: 液固比为6、pH7.3、酶量1000 u/g原料、搅拌速度200 r/min、45oC酶解90 min; 最优萃取条件: 萃取剂100 mL(每20 g鱼糜原料)、pH4.0、40oC萃取25 min; 离心条件: 离心速度3000 r/min (1865 g)、离心时间10 min。上述工艺条件下提油率为79.90%。改进了传统的鱼油提取工艺, 在活性成分保护上有较大改善。     

Minimising immunohistochemical false negative ER classification using a complementary 23 gene expression signature of ER status

Background

Expression of the oestrogen receptor (ER) in breast cancer predicts benefit from endocrine therapy. Minimising the frequency of false negative ER status classification is essential to identify all patients with ER positive breast cancers who should be offered endocrine therapies in order to improve clinical outcome. In routine oncological practice ER status is determined by semi-quantitative methods such as immunohistochemistry (IHC) or other immunoassays in which the ER expression level is compared to an empirical threshold[1], [2]. The clinical relevance of gene expression-based ER subtypes as compared to IHC-based determination has not been systematically evaluated. Here we attempt to reduce the frequency of false negative ER status classification using two gene expression approaches and compare these methods to IHC based ER status in terms of predictive and prognostic concordance with clinical outcome.

Methodology/Principal Findings

Firstly, ER status was discriminated by fitting the bimodal expression of ESR1 to a mixed Gaussian model. The discriminative power of ESR1 suggested bimodal expression as an efficient way to stratify breast cancer; therefore we identified a set of genes whose expression was both strongly bimodal, mimicking ESR expression status, and highly expressed in breast epithelial cell lines, to derive a 23-gene ER expression signature-based classifier. We assessed our classifiers in seven published breast cancer cohorts by comparing the gene expression-based ER status to IHC-based ER status as a predictor of clinical outcome in both untreated and tamoxifen treated cohorts. In untreated breast cancer cohorts, the 23 gene signature-based ER status provided significantly improved prognostic power compared to IHC-based ER status (P = 0.006). In tamoxifen-treated cohorts, the 23 gene ER expression signature predicted clinical outcome (HR = 2.20, P = 0.00035). These complementary ER signature-based strategies estimated that between 15.1% and 21.8% patients of IHC-based negative ER status would be classified with ER positive breast cancer.

Conclusion/Significance

Expression-based ER status classification may complement IHC to minimise false negative ER status classification and optimise patient stratification for endocrine therapies.